Novartis Completes Submissions In US And Europe For Glivec As Treatment For Four Rare Types Of Cancer

... Novartis announced today that it has submitted applications in the United States and Europe for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) Tablets in the U.S. as treatment for four rare types of cancer. These filings underscore how cancers of different origin and location can share common pathways that respond to the same targeted treatment... click link for more info. ...